Both RNA and DNA oncolytic viruses have been used in the few clinical studies in ovarian cancer; all the clinical studies did not proceed after phase I or are recruiting patients for phase I. Measles viruses expressing the carcinoembryonic antigen (CEA) were used in a phase I trial administered intraperitoneally in advanced stage cases [35]. The gene discussed is CEACAM5; the disease is ovarian cancer.